MIMEDX GROUP, INC.

Analyst Reco. MiMedx Group, Inc.

Equities

MDXG

US6024961012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.27 ^USD	+0.40%		-0.32%	-28.51%

Mar. 27	MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products	MT
Mar. 27	MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lake Street Starts MiMedx Group With Buy Rating, $12 Price Target	Mar. 07	MT
Mizuho Securities Raises Price Target on MiMedx to $14 From $13, Maintains Buy Rating	Mar. 01	MT
Mizuho Securities Adjusts MiMedx Price Target to $12 From $14, Maintains Buy Rating	23-10-31	MT
Mizuho Adjusts Price Target on MiMedx Group to $12 From $10, Maintains Buy Rating	23-08-02	MT
HC Wainwright Adjusts Price Target on MiMedx Group to $11 From $8, Maintains Buy Rating	23-08-02	MT
HC Wainwright Adjusts Price Target on Medx Group to $8 From $9.50, Keeps Buy Rating	23-06-21	MT
HC Wainwright Adjusts Price Target on MiMedx Group to $9.50 From $8, Maintains Buy Rating	23-05-03	MT
Mizuho Securities Starts MiMedx Group at Buy With $7 Price Target	22-10-13	MT
HC Wainwright Adjusts MiMedx Group's Price Target to $8 from $8.50, Reiterates Buy Rating	22-09-07	MT
MIMEDX : HC Wainwright Adjusts Price Target for MiMedx Group to $8.50 From $20, Maintains Buy Rating	21-09-14	MT
MIMEDX : Northland Capital Reinstates MiMedx Group at Outperform with $23 Price Target	21-07-26	MT
MIMEDX : HC Wainwright Starts MiMedx Group at Buy With $20 Price Target	21-03-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer